Recruiting
VyClo ITCC-092
2023-508050-26-00· Phase 1· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source
Active, not recruiting
A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)
NCT06962852· Phase 1/2· Boehringer Ingelheim· Source
Recruiting
A Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Than 6 Years Old
2024-511823-32-00· Phase 2· Italfarmaco S.p.A.· Source
Active, not recruiting
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706· Phase 2· Eli Lilly and Company· Source
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103· Phase 1/2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534· Phase 3· AbbVie· Source
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744· Phase 3· AbbVie· Source
Recruiting
Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with relapsed/refractory B-cell Acute Lymphoblastic Leukemia
2023-508420-36-00· Phase 1· Ospedale Pediatrico Bambino Gesu'· Source
Active, not recruiting
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
NCT06073132· Phase 2/3· TWi Biotechnology, Inc.· Source
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310· Phase 3· AstraZeneca· Source
Recruiting
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
NCT05933057· Phase 3· Italfarmaco· Source
Active, not recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353· Phase 3· AbbVie· Source
Not yet recruiting
A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, βS/βC Genotype
2023-503247-34-00· Phase 3· Vertex Pharmaceuticals Inc.· Source
Active, not recruiting
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
NCT06021522· Phase 3· Emalex Biosciences Inc.· Source
Active, not recruiting
Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis
NCT05644561· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Enrolling by invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949· Phase 3· AbbVie· Source
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085· Phase 2/3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394· Phase 3· AbbVie· Source
Recruiting
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
NCT05767047· Phase 3· Amgen· Source
Recruiting
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
NCT05611801· Phase 3· Pfizer· Source
Recruiting
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
2023-504264-41-00· Phase 1/2· F. Hoffmann-La Roche AG· Source
Active, not recruiting
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035· Phase 3· PedAL BCU, LLC· Source
Active, not recruiting
Clinical study testing the efficacy and safety of Ravulizumab in pediatric patients with NMOSD
2023-508534-33-00· Phase 2/3· Alexion Pharmaceuticals Inc.· Source
Active, not recruiting
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Recruiting
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553· Phase 3· Amgen· Source
Active, not recruiting
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
NCT05309668· Phase 1/2· AstraZeneca· Source
Recruiting
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172· Phase 3· H. Lundbeck A/S· Source
Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986· Phase 2· Travere Therapeutics, Inc.· Source
Active, not recruiting
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
NCT04624659· Phase 3· Forma Therapeutics, Inc.· Source
Enrolling by invitation
A Long-term Follow-up Study in Participants Who Received CTX001
NCT04208529· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
NCT04175600· Phase 3· Actelion· Source
Active, not recruiting
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
NCT04075266· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
NCT04006808· Phase 1/2· GlaxoSmithKline· Source
Recruiting
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
NCT04832607· Phase 3· Tobias Feuchtinger· Source
Active, not recruiting
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
NCT03725007· Phase 1· AbbVie· Source
Active, not recruiting
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
NCT03591510· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
NCT02991469· Phase 2· Sanofi· Source
Active, not recruiting
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
NCT03407144· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
NCT03363373· Phase 2· Y-mAbs Therapeutics· Source
Active, not recruiting
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
NCT02979522· Phase 1/2· Takeda· Source
Active, not recruiting
Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiotherapy and multiple elective radiotherapy courses with concomitant vinorelbine and nimotuzumab for newly diagnosed childhood and adolescence diffuse intrinsic pontine glioma (DIPG).
2024-513654-30-00· Phase 2· Fondazione IRCCS Istituto Nazionale Dei Tumori· Source
Recruiting
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT02332668· Phase 1/2· Merck Sharp & Dohme LLC· Source